BRUKINSA, 미치료 만성 림프구성 백혈병(CLL) 환자 대상 6년 무진행 생존율(PFS) 74% 달성이라는 획기적인 성과 발표
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population.
BRUKINSA demonstrated 74% 6-year PFS in treatment-naïve CLL patients.
百济神州公布了一项III期研究的里程碑数据，显示BRUKINSA在初治慢性淋巴细胞白血病（CLL）患者中实现了六年74%的无进展生存率（PFS）。这一重要的长期疗效数据巩固了BRUKINSA作为CLL领先治疗选择的地位。
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population. For APAC, where CLL is a significant concern, these results reinforce the value of BRUKINSA as a long-term treatment option, potentially improving patient outcomes and quality of life across the region.
BRUKINSA is a key product for BeiGene in APAC. Demonstrating such strong long-term efficacy in treatment-naïve CLL patients is highly relevant for oncologists and patients in the region, supporting its continued adoption and clinical use.
Where this signal fits in the broader landscape.
BeiGene, 2025년 4분기 및 연간 재무 실적 발표
BeiGene, 2025년 4분기 및 연간 재무 실적 발표
BeOne Medicines, 2025년 4분기 및 회계연도 재무 실적 발표
BeiGene의 PD-1 억제제 티슬렐리주맙, 일본 승인 획득…글로벌 제약 공룡에 도전장
BeOne Medicines, 2025년 4분기 및 연간 재무 실적 발표 예정
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-percent-6-year-progression-free-survival-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인